Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.
2.

Whither surgical quality assurance of breast cancer surgery (surgical margins and local recurrence) after paterson.

Bundred NJ, Thomas J, Dixon JMJ.

Breast Cancer Res Treat. 2017 Oct;165(3):473-475. doi: 10.1007/s10549-017-4369-3. Epub 2017 Jul 5.

PMID:
28681172
3.

Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.

Loncaster J, Armstrong A, Howell S, Wilson G, Welch R, Chittalia A, Valentine WJ, Bundred NJ.

Eur J Surg Oncol. 2017 May;43(5):931-937. doi: 10.1016/j.ejso.2016.12.010. Epub 2017 Jan 9. Erratum in: Eur J Surg Oncol. 2017 Nov 23;:.

4.

Recruitment to the "Breast-Activity and Healthy Eating After Diagnosis" (B-AHEAD) Randomized Controlled Trial.

Pegington M, Adams JE, Bundred NJ, Campbell AM, Howell A, Howell SJ, Speed S, Wolstenholme J, Harvie MN.

Integr Cancer Ther. 2018 Mar;17(1):131-137. doi: 10.1177/1534735416687850. Epub 2017 Jan 23.

5.

Tissue Factor promotes breast cancer stem cell activity in vitro.

Shaker H, Harrison H, Clarke R, Landberg G, Bundred NJ, Versteeg HH, Kirwan CC.

Oncotarget. 2017 Apr 18;8(16):25915-25927. doi: 10.18632/oncotarget.13928.

6.

Prediction of margin involvement and local recurrence after skin-sparing and simple mastectomy.

Al-Himdani S, Timbrell S, Tan KT, Morris J, Bundred NJ.

Eur J Surg Oncol. 2016 Jul;42(7):935-41. doi: 10.1016/j.ejso.2016.04.055. Epub 2016 May 3.

PMID:
27256869
7.

PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.

Kirwan CC, Bundred NJ, Castle J, Clarke R, Dive C, Morris J, Holcombe C, Harvey JR.

Thromb Res. 2016 Apr;140 Suppl 1:S189-90. doi: 10.1016/S0049-3848(16)30169-4. Epub 2016 Apr 8.

PMID:
27161723
8.

PO-21 - Stromal fibroblasts in preinvasive breast cancer (ductal carcinoma in situ, DCIS) demonstrate a cancer-like procoagulant phenotypic switch that may facilitate invasion.

Shaker H, Bundred NJ, Albadry H, Nicholson S, Castle J, Lumsden LJ, Pritchard S, Landberg G, Kirwan CC.

Thromb Res. 2016 Apr;140 Suppl 1:S184. doi: 10.1016/S0049-3848(16)30154-2. Epub 2016 Apr 8.

PMID:
27161710
9.

A randomised pilot study comparing 13 G vacuum-assisted biopsy and conventional 14 G core needle biopsy of axillary lymph nodes in women with breast cancer.

Maxwell AJ, Bundred NJ, Harvey J, Hunt R, Morris J, Lim YY.

Clin Radiol. 2016 Jun;71(6):551-7. doi: 10.1016/j.crad.2016.02.024. Epub 2016 Mar 31.

PMID:
27040801
10.

Randomized controlled trial of stereotactic 11-G vacuum-assisted core biopsy for the diagnosis and management of mammographic microcalcification.

Bundred SM, Maxwell AJ, Morris J, Lim YY, Harake MJ, Whiteside S, Bundred NJ.

Br J Radiol. 2016;89(1058):20150504. doi: 10.1259/bjr.20150504. Epub 2015 Dec 14.

11.

Comparison of multi-frequency bioimpedance with perometry for the early detection and intervention of lymphoedema after axillary node clearance for breast cancer.

Bundred NJ, Stockton C, Keeley V, Riches K, Ashcroft L, Evans A, Skene A, Purushotham A, Bramley M, Hodgkiss T; Investigators of BEA/PLACE studies.

Breast Cancer Res Treat. 2015 May;151(1):121-9. doi: 10.1007/s10549-015-3357-8. Epub 2015 Apr 8.

PMID:
25850535
12.

Molecular phenotypes of DCIS predict overall and invasive recurrence.

Williams KE, Barnes NL, Cramer A, Johnson R, Cheema K, Morris J, Howe M, Bundred NJ.

Ann Oncol. 2015 May;26(5):1019-25. doi: 10.1093/annonc/mdv062. Epub 2015 Feb 12.

PMID:
25678586
13.

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ.

Lancet Oncol. 2014 Nov;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7. Epub 2014 Oct 15.

14.

Is axillary lymph node clearance required in node-positive breast cancer?

Bundred NJ, Barnes NL, Rutgers E, Donker M.

Nat Rev Clin Oncol. 2015 Jan;12(1):55-61. doi: 10.1038/nrclinonc.2014.188. Epub 2014 Nov 4. Review.

PMID:
25367714
15.

Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.

Williams KE, Bundred NJ, Landberg G, Clarke RB, Farnie G.

Stem Cells. 2015 Feb;33(2):327-41. doi: 10.1002/stem.1843.

16.

The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast.

Barnes NL, Dimopoulos N, Williams KE, Howe M, Bundred NJ.

Eur J Surg Oncol. 2014 Mar;40(3):249-54. doi: 10.1016/j.ejso.2013.12.013. Epub 2014 Jan 3.

PMID:
24433818
17.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

18.

Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS).

Farnie G, Johnson RL, Williams KE, Clarke RB, Bundred NJ.

Cell Cycle. 2014;13(3):418-25. doi: 10.4161/cc.27201. Epub 2013 Nov 18.

19.

Targeting IL-8 signalling to inhibit breast cancer stem cell activity.

Singh JK, Simões BM, Clarke RB, Bundred NJ.

Expert Opin Ther Targets. 2013 Nov;17(11):1235-41. doi: 10.1517/14728222.2013.835398. Epub 2013 Sep 14.

PMID:
24032691
21.

Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.

Farnie G, Willan PM, Clarke RB, Bundred NJ.

PLoS One. 2013;8(2):e56840. doi: 10.1371/journal.pone.0056840. Epub 2013 Feb 14.

22.

Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.

Singh JK, Farnie G, Bundred NJ, Simões BM, Shergill A, Landberg G, Howell SJ, Clarke RB.

Clin Cancer Res. 2013 Feb 1;19(3):643-56. doi: 10.1158/1078-0432.CCR-12-1063. Epub 2012 Nov 13.

23.

Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?

Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A, Aapro MS.

Cancer Treat Rev. 2012 Oct;38(6):798-806. doi: 10.1016/j.ctrv.2012.02.008. Epub 2012 Mar 18. Review.

PMID:
22429722
24.

Ductal carcinoma in situ of the breast.

Barnes NL, Ooi JL, Yarnold JR, Bundred NJ.

BMJ. 2012 Feb 29;344:e797. doi: 10.1136/bmj.e797. Review. No abstract available.

PMID:
22378935
25.

Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy.

Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, Schoultz Bv, Vassilopoulou-Sellin R, Galta RE, Lieshout EV, Mol-Arts M, Planellas J, Kubista E.

Breast Cancer Res. 2012 Jan 17;14(1):R13.

26.

Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?

Bundred NJ, Prasad R, Morris J, Knox WF, Byrne G, Cheung S, Wilson M, Lawrence G.

Breast Cancer Res Treat. 2013 Apr;138(2):359-68. doi: 10.1007/s10549-011-1652-6. Epub 2011 Jul 10.

PMID:
21744241
27.

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.

Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A.

Ann Oncol. 2011 Dec;22(12):2546-55. doi: 10.1093/annonc/mdr017. Epub 2011 Mar 17. Review.

PMID:
21415233
28.

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD.

Lancet Oncol. 2011 Jan;12(1):21-9. doi: 10.1016/S1470-2045(10)70266-7. Epub 2010 Dec 7.

29.

Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.

Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, Johnson R, Young O, Landberg G, Grassby S, Turner L, Baildam A, Barr L, Dixon JM.

Clin Cancer Res. 2010 Mar 1;16(5):1605-12. doi: 10.1158/1078-0432.CCR-09-1623. Epub 2010 Feb 23.

30.

Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor.

Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB.

Cancer Res. 2010 Jan 15;70(2):709-18. doi: 10.1158/0008-5472.CAN-09-1681. Epub 2010 Jan 12.

31.

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ, Streuli CH.

Breast Cancer Res. 2009;11(3):R41. doi: 10.1186/bcr2328. Epub 2009 Jun 29.

32.

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.

Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group.

Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23.

33.

Aromatase inhibitors and bone health.

Bundred NJ.

Curr Opin Obstet Gynecol. 2009 Feb;21(1):60-7. doi: 10.1097/GCO.0b013e32831da80e. Review.

PMID:
19125005
34.

Response and resistance to the endocrine prevention of breast cancer.

Howell A, Bundred NJ, Cuzick J, Allred DC, Clarke R.

Adv Exp Med Biol. 2008;617:201-11. doi: 10.1007/978-0-387-69080-3_19. Review.

PMID:
18497044
35.

Idiopathic granulomatous mastitis: a 25-year experience.

Al-Khaffaf B, Knox F, Bundred NJ.

J Am Coll Surg. 2008 Feb;206(2):269-73. doi: 10.1016/j.jamcollsurg.2007.07.041. Epub 2007 Oct 29.

PMID:
18222379
36.

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.

Cancer. 2008 Mar 1;112(5):1001-10. doi: 10.1002/cncr.23259.

37.

To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?

Iddon J, Bundred NJ.

Expert Rev Anticancer Ther. 2008 Jan;8(1):9-13. Review.

PMID:
18095878
38.

Safety of tibolone in the treatment of vasomotor symptoms in breast cancer patients--design and baseline data 'LIBERATE' trial.

Kenemans P, Kubista E, Foidart JM, Yip CH, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Beckmann MW, Bundred NJ, Egberts J, van Os S, Planellas J.

Breast. 2007 Dec;16 Suppl 2:S182-9. Erratum in: Breast. 2008 Apr;17(2):214-5. Egberts, J [added]; van Os, S [added]; Planellas, J [added].

39.

Serum vascular endothelial growth factor in breast cancer.

Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ.

Anticancer Res. 2007 Sep-Oct;27(5B):3481-7.

40.

Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer.

Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, Kumar S, Bundred NJ.

Int J Oncol. 2007 Nov;31(5):1127-32.

PMID:
17912439
41.

Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways.

Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG, Bundred NJ.

J Natl Cancer Inst. 2007 Apr 18;99(8):616-27.

PMID:
17440163
42.

Prevention of venous thromboembolism in surgical patients with breast cancer.

Patiar S, Kirwan CC, McDowell G, Bundred NJ, McCollum CN, Byrne GJ.

Br J Surg. 2007 Apr;94(4):412-20. Review.

PMID:
17380560
43.

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.

Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ.

Br J Cancer. 2007 Feb 26;96(4):575-82. Epub 2007 Feb 6.

44.

Optimising bone health in survivors of breast cancer.

Bundred NJ.

Lancet Oncol. 2007 Feb;8(2):89-91. No abstract available.

PMID:
17267320
45.

Breast pain.

Bundred NJ.

BMJ Clin Evid. 2007 Apr 1;2007. pii: 0812. Review.

46.

Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.

Wilson GR, Cramer A, Welman A, Knox F, Swindell R, Kawakatsu H, Clarke RB, Dive C, Bundred NJ.

Br J Cancer. 2006 Nov 20;95(10):1410-4. Epub 2006 Oct 24.

47.

Letrozole: a well-tolerated and effective treatment for breast cancer.

Bundred NJ.

Womens Health (Lond). 2006 Sep;2(5):673-85. doi: 10.2217/17455057.2.5.673.

PMID:
19803820
48.

Current UK practice of thromboprophylaxis for breast surgery.

Kirwan CC, McCollum CN, Bundred NJ, Byrne GJ.

Br J Surg. 2006 Oct;93(10):1224-5. No abstract available.

PMID:
16862614
49.
50.

Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.

Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ.

Br J Cancer. 2006 Jan 30;94(2):253-8.

Supplemental Content

Loading ...
Support Center